Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Spikes on Zontivity Launch | Stock News Union

From Arlez Pharmaceuticals press release: “We are encouraged by the early data following the launch of Zontivity® and we will continue to monitor prescribing data closely over the next few quarters to determine whether this trend continues,” Aralez Pharmaceutical’s in a statement.

Sales Force Reductions

Aralez has carried out a 32% U.S sales force reduction on Yosprala, a combination aspirin drug for the prevention of cardiovascular and cerebrovascular events. The move follows lackluster launch that appears to have hurts sales.  In a bid to accelerate sales, the company has initiated a new pricing strategy that will allow patients to access the drug for only $10 a month regardless of whether one has an insurance cover or not.

Separately, a U.S District Court has upheld the validity of two patents owned by Aralez Subsidiary covering VIMOVO, a non-steroidal drug for treating signs and symptoms of osteoarthritis.

Read complete article here:

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Spikes on Zontivity Launch – Stock News Union.